Precigen Inc (PGEN)

2.140
-0.040(-1.84%)
  • Volume:
    196,756
  • Day's Range:
    2.125 - 2.220
  • 52 wk Range:
    1.120 - 5.600

PGEN Overview

Prev. Close
2.18
Day's Range
2.125-2.22
Revenue
54.2M
Open
2.13
52 wk Range
1.12-5.6
EPS
-0.459
Volume
196,756
Market Cap
450.64M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,577,584
P/E Ratio
-5.27
Beta
2.28
1-Year Change
-58.79%
Shares Outstanding
208,150,021
Next Earnings Date
Nov 07, 2022
What is your sentiment on Precigen?
or
Vote to see community's results!

Precigen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Precigen Inc Analysis

Precigen Inc Company Profile

Precigen Inc Company Profile

Employees
484

Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.

Read More

Analyst Price Target

Average12.200 (+463.51% Upside)
High17
Low6
Price2.165
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 20% bump today with FDA orphan drug designation.
    0
    • PGEN $8.20 -2.84% @ Close (Earnings)
      0
      • PGEN $8.27 +0.61% @ Close! Sideways since exit, but holding tough in a weaker NASDQ market.
        0
        • PGEN $8.33 @ Friday Close!
          0
          • PGEN $8.30 @ 12:52 PM ET ... Stopped on 1/2 bull. Flat of PGEN
            0
            • PGEN $8.80 +1.15% ... raising bull stop to $8.30 from $7.30. @ 02:30 PM ET.
              0
              • PGEN $8.10 @ Friday close!
                0
                • This week's trade at $7.50 is a triple bottom sell signal, which negates the previously noted bull vertical count. My stop loss is firm $7.35. The trade at $7.50 could be a "bear trap" should we get a reversal back up to $10.00, which would get the shares back on a buy signal. Bullish support trend @ $6.50.
                  0
              • PGEN .... brought to my attention by Guns and Glory in VX chat 1/26/2021.  Bull vertical count to $19.50 is upper end of retracement.  Recent Secondary Offering at $7.50.  Secondary probably shorted by underwriters as a hedge, but they are covered.  However, sell side firms may be short, undhedged, belief that secondary is diluted.  #11 on NASDAQ short interest and good environment for a short squeeze. https://invst.ly/tluey
                0
                • Very bullish from 2nd June, when a fund bought a lot of shares.
                  0
                  • buy or sell?
                    0
                    • Buy. Its up today 20%
                      0